SAN DIEGO--(BUSINESS WIRE)--DJO Incorporated (NYSE:DJO), a global provider of products and services that promote musculoskeletal and vascular health, today announced that it has received FDA approval for a supplement to the Company’s existing Pre-Market Approval (PMA). The PMA supplement covers several new product features that are built into the control modules for its Combined Magnetic Field (CMF) OL1000 and SpinaLogic® bone growth stimulation product lines. The new product features enhance patients’ ease of use.
